Alzheimer's disease trials recruiting in California

All Alzheimer's disease trials nationally

Cities in California

Recruiting trials in California

• A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  NCT07033494 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · California: Irvine, Long Beach, Los Angeles, Redlands
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · California: Imperial, Long Beach, Oakland, Riverside
• A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
  NCT07094516 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · California: Irvine, La Jolla, Los Angeles
• A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
  NCT05452031 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · California: La Jolla, Los Angeles
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Garden Grove, Long Beach, Napa, Orange
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Anaheim, La Jolla, Pomona, Torrance
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · California: Huntington Beach, Irvine, Long Beach, Riverside
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
  NCT07589595 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · California: Carlsbad, Irvine, La Jolla, Palo Alto
• A Study of LY3439539 in Participants With Alzheimer's Disease
  NCT07598370 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · California: Irvine, Long Beach, Los Angeles
• A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
  NCT06657768 · Phase: Phase 1 · Ages: 45 Years to 85 Years · Sex: All (male and female) · California: Los Alamitos
• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT05552157 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: La Jolla, Los Angeles
• A Study of Psychedelics in Healthy Older Adults With Low Well-being
  NCT07386730 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · California: San Francisco
• A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
  NCT07717411 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · California: Irvine, Santa Ana
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07169578 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · California: Irvine, Los Angeles, San Francisco, Santa Ana
• A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
  NCT07633470 · Phase: Phase 4 · Ages: 50 Years and older · Sex: All (male and female) · California: Orange
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT06647498 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: La Jolla, Los Angeles
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
  NCT05511363 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Encino, Irvine, Orange, Pasadena
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
  NCT06126224 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Anaheim, Canoga Park, Encino, Lancaster
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
  NCT06651567 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female) · California: Anaheim, Costa Mesa, Garden Grove, Newport Beach
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
  NCT06540833 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female) · California: Anaheim, Los Alamitos, Newport Beach, Orange
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
  NCT06887192 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Anaheim, Long Beach, Murrieta, Orange
• A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
  NCT07599670 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 90 Years · Sex: All (male and female) · California: Irvine
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Anaheim, Chino, Long Beach, Los Angeles
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Chino
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
  NCT06976216 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · California: Long Beach, Redlands
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · California: Fullerton, Irvine, Los Angeles, Palo Alto
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Anaheim, Fresno, Long Beach, Orange
• A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
  NCT05231785 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · California: La Jolla
• ACP-204 in Adults With Alzheimer's Disease Psychosis
  NCT06159673 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 95 Years · Sex: All (male and female) · California: Anaheim, Costa Mesa, Fresno, Garden Grove
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
  NCT06563895 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · California: La Jolla, Los Angeles, San Francisco, Stanford
• Alzheimer Prevention Trials (APT) Webstudy
  NCT03638583 · Phase: Not specified · Ages: 50 Years to 85 Years · Sex: All (male and female) · California: San Diego
• Alzheimer's Tau Platform: Master Protocol
  NCT06957418 · Phase: Phase 2 · Ages: 50 Years to 80 Years · Sex: All (male and female) · California: San Francisco
• Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
  NCT05667649 · Phase: Phase 1 · Ages: 45 Years to 80 Years · Sex: All (male and female) · California: Newport Beach
• Biomarker Exploration in Aging, Cognition and Neurodegeneration
  NCT03860857 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · California: Irvine
• Bumetanide in Patients With Alzheimer's Disease
  NCT06052163 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · California: Stanford
• Cardiac-Control Affecting Learning Through Mindfulness (CALM)
  NCT06410157 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 70 Years · Sex: All (male and female) · California: Los Angeles
• Caring Recharge Project for Caregivers of Individuals With Alzheimer's Disease
  NCT07764185 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · California: Campbell
• Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project
  NCT02434393 · Phase: Not specified · Ages: 65 Years and older · Sex: All (male and female) · California: San Francisco
• Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
  NCT06189963 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · California: Glendale, Santa Ana, Tarzana
• Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease
  NCT04800588 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 89 Years · Sex: All (male and female) · California: Berkeley
• Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
  NCT06052254 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · California: Chino
• Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the Lifespan
  NCT07763392 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · California: Carlsbad
• Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
  NCT05929703 · Phase: Not applicable (e.g. observational or device study) · Ages: 70 Years and older · Sex: All (male and female) · California: Orange
• FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
  NCT06539169 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · California: Los Altos
• First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
  NCT05374278 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 75 Years · Sex: All (male and female) · California: San Francisco
• Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)
  NCT06597942 · Phase: Phase 1, Phase 2 · Ages: 55 Years to 100 Years · Sex: All (male and female) · California: Los Angeles
• Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
  NCT05397639 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · California: Anaheim, Costa Mesa, Encino, Fresno
• Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
  NCT04684602 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · California: Culver City
• Open-Label Extension Protocol to SNK01-AD01 Study
  NCT07228078 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · California: Glendale
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Anaheim, Chino, Costa Mesa, Encino
• Polyphenols and Cognitive Decline
  NCT06507254 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years and older · Sex: All (male and female) · California: Los Angeles
• Predicting Pre-dementia
  NCT07516119 · Phase: Not specified · Ages: 55 Years and older · Sex: All (male and female) · California: San Diego
• Promoting Physical Activity in Older Hispanic/Latino(a) Adults
  NCT06362824 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years to 89 Years · Sex: All (male and female) · California: San Diego
• Remotely-supervised Neuromodulation in PPA
  NCT07260253 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · California: San Francisco
• Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
  NCT04500847 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · California: Los Angeles
• Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
  NCT07178210 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years and older · Sex: All (male and female) · California: Palo Alto
• Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
  NCT07284472 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Murrieta
• Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
  NCT05395624 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · California: San Francisco, Stanford
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
  NCT07177352 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · California: Imperial, Inglewood, Irvine, Long Beach
• Senicapoc in Alzheimer's Disease
  NCT04804241 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · California: Sacramento, Walnut Creek
• Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
  NCT06932809 · Phase: Early Phase 1 · Ages: 40 Years to 85 Years · Sex: All (male and female) · California: San Francisco
• Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
  NCT06847321 · Phase: Phase 2 · Ages: 55 Years to 80 Years · Sex: All (male and female) · California: Oakland, Orange, Riverside, Sherman Oaks
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
  NCT06808984 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · California: Anaheim, Chino, La Jolla, Lakewood
• TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
  NCT06548191 · Phase: Phase 1 · Ages: 60 Years and older · Sex: All (male and female) · California: San Diego
• Testing & Refinement of CarePair: An Assessment and Referral Platform to Support Family Caregivers of Alzheimer's Disease and Related Dementias.
  NCT06418971 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · California: Los Angeles
• Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
  NCT07224607 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years to 89 Years · Sex: All (male and female) · California: Los Angeles
• Trial-Ready Cohort-Down Syndrome (TRC-DS)
  NCT04165109 · Phase: Not specified · Ages: 25 Years to 55 Years · Sex: All (male and female) · California: Orange
• [18F]PI-2620 Phase 3 Histopathological Study
  NCT05641688 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · California: Los Angeles, Murrieta, San Francisco